Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: Thiazolidinediones (glitazones) have enhanced activity under high glucose conditions

Cardiovascular Diabetology

Volumn 6, Issue , 2007, Pages

  Little, Peter J ^a,b   Osman, Narin ^a,b   de Dios, Stephanie T ^b,c   Cemerlang, Nelly ^b   Ballinger, Mandy ^b   Nigro, Julie ^b,d  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; DNA; GLICLAZIDE; GLITAZONE DERIVATIVE; GLUCOSE; METFORMIN; ORAL ANTIDIABETIC AGENT; PHENFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; THYMIDINE KINASE; TRITIUM; TROGLITAZONE; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; THYMIDINE;

ARTICLE; CARDIOVASCULAR DISEASE; CELL COUNT; CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DIABETES MELLITUS; DIABETIC PATIENT; DNA SYNTHESIS; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; FETAL CALF SERUM; FLUORESCENCE ACTIVATED CELL SORTING; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; SMOOTH MUSCLE FIBER; STATISTICAL SIGNIFICANCE; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; CELL DIVISION; CYTOLOGY; DRUG EFFECT; MAMMARY ARTERY; METABOLISM; PHYSIOLOGY; SAPHENOUS VEIN;

CELL DIVISION; CELLS, CULTURED; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; MAMMARY ARTERIES; MUSCLE, SMOOTH, VASCULAR; SAPHENOUS VEIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; THYMIDINE;

EID: 38549125571     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-6-33     Document Type: Article

References (39)

1. Ross R The pathogenesis of atherosclerosis N Engl J Med 1986, 314:488-500. 3511384
2. Kornowski R Mintz GS Kent KM Pichard AD Satler F Bucher TA Hong MK Popma JJ Leon MB Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia Circulation 1997, 95:1366-1369. 9118501
3. Ferguson JJ NHLBI BARI clinical alert on diabetes treated with angioplasty Circulation 1995, 92:3371. 8521550
4. Choi D Kim SK Choi SH Ko YG Ahn CW Jang Y Lim SK Lee HC Cha BS Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes Diabetes Care 2004, 27:2654-60. 10.2337/diacare.27.11.2654 15505001
5. Takagi T Akasaka T Yamamuro A Honda Y Hozumi T Morioka S Yoshida K Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study J Am Coll Cardiol 2000, 36:1529-35. 10.1016/S0735-1097(00)00895-0 11079654
6. Williams KJ Tabas I The response-to-retention hypothesis of early atherogenesis Arterioscler Thromb Vasc Biol 1995, 15:551-61. 7749869
7. Nakashima Y Fujii H Sumiyoshi S Wight TN Sueishi K Early human atherosclerosis: Accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration Arterioscler Thromb Vasc Biol 2007, 27:1159-65. 10.1161/ATVBAHA.106.134080 17303781
8. Libby P Inflammation in atherosclerosis Nature 2002, 420:868-74. 10.1038/ nature01323 12490960
9. Ross R Atherosclerosis - an inflammatory disease N Engl J Med 1999, 340:115-26. 10.1056/NEJM199901143400207 9887164
10. Weissman P Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus Am J Cardiol 2002, 90:42G-50G. 10.1016/ S0002-9149(02)02558-4 12231078
11. Sidhu JS Kaposzta Z Markus HS Kaski JC Effect of Rosiglitazone on Common Carotid Intima-Media Thickness Progression in Coronary Artery Disease Patients Without Diabetes Mellitus Arterioscler Thromb Vasc Biol 2004, 24:930-934. 10.1161/01.ATV.0000124890.40436.77 15001452
12. de Dios ST Bruemmer D Dilley RJ Ivey ME Jennings GL Law RE Little PJ Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation Circulation 2003, 107:2548-50. 10.1161/ 01.CIR.0000074040.31731.96 12742988
13. Little PJ Allen TJ Hashimura K Nigro J Farrelly CA Dilley RJ High glucose potentiates mitogenic responses of cultured ovine coronary smooth muscle cells to platelet derived growth factor and transforming growth factor-beta1 Diabetes Res Clin Pract 2003, 59:93-101. 10.1016/ S0168-8227(02)00201-2 12560158
14. Agrotis A Little PJ Saltis J Bobik A Dihydropyridine Ca2+ channel antagonists inhibit the salvage pathway for DNA synthesis in human vascular smooth muscle cells Eur J Pharmacol 1993, 244:269-75. 10.1016/ 0922-4106(93)90152-Y 8458401
15. Takeda K Ichiki T Tokunou T Iino N Takeshita A 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells J Biol Chem 2001, 276:48950-5. 10.1074/jbc.M108722200 11687581
16. Ross R JA G Kariya B Harker L A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro Proc Natl Acad Sci USA 1974, 71:1207-1210. 388193 4208546 10.1073/ pnas.71.4.1207
17. Zhang Q Lu L Pu L Zhang R Shen J Zhu Z Hu J Yang Z Chen Q Shen W Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine Cardiovasc Diabetol 2007, 6:16. 1892541 17550588 10.1186/1475-2840-6-16
18. Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007, 356:2457-71. 10.1056/NEJMoa072761 17517853
19. Diamond GA Bax L Kaul S Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death Ann Intern Med 2007.
20. Sato A Sasaoka T Yamazaki K Nakamura N Temaru R Ishiki M Takata M Kishida M Wada T Ishihara H Glucosamine enhances platelet-derived growth factor-induced DNA synthesis via phosphatidylinositol 3-kinase pathway in rat aortic smooth muscle cells Atherosclerosis 2001, 157:341-52. 10.1016/S0021-9150(00)00740-1 11472733
21. Ling S Little PJ Williams MR Dai A Hashimura K Liu JP Komesaroff PA Sudhir K High glucose abolishes the antiproliferative effect of 17beta-estradiol in human vascular smooth muscle cells Am J Physiol Endocrinol Metab 2002, 282:E746-51. 11882493
22. Gomperts BD Kramer IM Tatham PER Signal Transduction San Diego: Elsevier Academic Press 2004.
23. Sperti G Colucci WS Calcium influx modulates DNA synthesis and proliferation in A7r5 vascular smooth muscle cells Eur J Pharmacol 1991, 206:279-84. 10.1016/0922-4106(91)90110-4 1915588
24. Lincoff AM Wolski K Nicholls SJ Nissen SE Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials Jama 2007, 298:1180-8. 10.1001/ jama.298.10.1180 17848652
25. DCCT The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial Diabetes 1996, 45:1289-1298. 10.2337/ diabetes.45.10.1289 8826962
26. Wei M Haffner SM Gaskill SP Stern MP Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality Diabetes Care 1998, 21:1167-1172. 10.2337/diacare.21.7.1167 9653614
27. Vasudevan AR Burns A Fonseca VA The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus Treat Endocrinol 2006, 5:273-86. 10.2165/ 00024677-200605050-00002 17002487
28. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 Br Med J 1998, 317:703-13.
29. Dormandy JA Charbonnel B Eckland DJ Erdmann E Massi-Benedetti M Moules IK Skene AM Tan MH Lefebvre PJ Murray GD Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 2005, 366:1279-89. 10.1016/ S0140-6736(05)67528-9 16214598
30. Plutzky J Medicine. PPARs as therapeutic targets: Reverse cardiology? Science 2003, 302:406-7. 10.1126/science.1091172 14563997
31. Marx N Schonbeck U Lazar MA Libby P Plutzky J Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells Circulation Research 1998, 83:1097-1103. 9831704
32. Collins AR Meehan WP Kintscher U Jackson S Wakino S Noh G Palinski W Hsueh WA Law RE Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice Arterioscler Thromb Vasc Biol 2001, 21:365-71. 11231915
33. Calkin AC Forbes JM Smith CM Lassila M Cooper ME Jandeleit-Dahm KA Allen TJ Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects Arterioscler Thromb Vasc Biol 2005, 25:1903-9. 10.1161/01.ATV.0000177813.99577.6b 16020748
34. Nigro J Ballinger ML Osman N Dart AM Little PJ Anti-atherogenic role of peroxisome proliferator activated receptor ligands Current Cardiology Reviews 2005, 1:89-102. 10.2174/1573403054021654
35. Libby P Inflammation and cardiovascular disease mechanisms Am J Clin Nutr 2006, 83:456S-460S. 16470012
36. Little PJ Ballinger ML Osman N Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis Vascular Health Risk Management 2007, 3:1-8.
37. de Dios ST Frontanilla KV Nigro J Ballinger ML Ivey ME Cawson EA Little PJ Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents J Diabetes Complications 2007, 21:108-17. 10.1016/j.jdiacomp.2006.03.003 17331859
38. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998, 352:854-65. 10.1016/S0140-6736(05)61359-1 9742977
39. Nigro J Osman N Dart AM Little PJ Insulin Resistance and Atherosclerosis Endocr Rev 2006, 27:242-259. 10.1210/er.2005-0007 16492903